AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21846985
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily gentamicin dosing
Trial: 17926624
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Hegu (LI 4), Neiguan (PC 6), and Zusanli (ST 36) combined with oral administration of Lidocaine
Trial: 17926624
Drug: Lidocaine administration
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine administration only
Trial: 15523006
Drug: Serial casting
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial casting combined with botulinum toxin A (Botox) injection
Trial: 11720760
Drug: Platin-based combination
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platin-based combination chemotherapy
Trial: 11720760
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent therapy with newer cytotoxic agents
Trial: 9246961
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments combined (IUI, DIPI, TI) with superovulation
Trial: 29952106
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with fractional radiofrequency microneedling and 5% topical minoxidil
Trial: 29952106
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with 5% topical minoxidil
Trial: 24905061
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) to Metformin (MET)
Trial: 18564781
Drug: 0.1% polyhexanide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% polyhexanide gel (Prontosan Gel)
Trial: 12456422
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 1)
Trial: 10605163
Drug: Carboplatin (CBCDA)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (CBCDA) 300 mg/m2 day 1, Vindesine (VDS) 3 mg/m2 days 1 and 5, leucovorin (L) 100 mg/m2, 5‐fluorouracil (5‐FU) 370 mg/m2 for 5 days, and 13‐cis retinoic acid (R) 1 mg/kg, administered between chemotherapy courses.
Trial: 1881957
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound using placebo cream (Group 1)
Trial: 1881957
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound using trolamine salicylate cream (Group 2)
Trial: 1881957
Drug: Ultrasound using
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound using placebo cream (Group 3)
Trial: 1881957
Drug: Ultrasound using
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound using trolamine salicylate cream (Group 4)
Trial: 6823882
Drug: Sustagen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustagen with 0 mg/kg MSG
Trial: 6823882
Drug: Sustagen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustagen with 100 mg/kg MSG
Trial: 6823882
Drug: Sustagen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustagen with 150 mg/kg MSG
Trial: 6823882
Drug: MSG in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSG in water (150 mg/kg)
Trial: 6823882
Drug: Sustagen with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustagen with MSG (all doses)
Trial: 29546309
Drug: Resveratrol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (200 mg) and Curcumin (100 mg)
Trial: 25548744
Drug: Candesartan and
RxNorm normalized name: candesartan and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan and propranolol combination therapy (26 patients)
Trial: 25548744
Drug: Propranolol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol monotherapy (27 patients)
Trial: 21908494
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy plus paroxetine
Trial: 15093982
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg/daily) for 6 weeks
Trial: 28340861
Drug: Aclidinium bromide/formoterol
RxNorm normalized name: Aclidinium Bromide/Formoterol Fumarate 400 MCG/1 ACTUATION-12 MCG/1 ACTUATION Inhalation Aerosol Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 μg
Trial: 12707658
Drug: Biofeedback rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback rehabilitation training method (30 minutes daily for 10 months)
Trial: 1419007
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 3 mg and IM saline
Trial: 1419007
Drug: Epidural saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural saline and IM morphine
Trial: 3907678
Drug: Flurbiprofen 400
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 400 mg daily for 48 h followed by 200 mg daily
Trial: 3907678
Drug: Phenylbutazone 800
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 800 mg daily for 48 h followed by 400 mg daily
Trial: 28214040
Drug: 7.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g/d AX (n=16)
Trial: 28214040
Drug: 15 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g/d AX (n=17)
Trial: 26962828
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA19‐9, CA15‐3, and kallikrein‐12
Trial: 22353593
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal polysaccharide vaccine (control)
Trial: 21258306
Drug: Hypertonic seawater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic seawater solution
Trial: 21258306
Drug: Isotonic seawater
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotonic seawater solution
Trial: 7645538
Drug: Subcutaneous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epoetin alfa (SC) three times per week
Trial: 7645538
Drug: Subcutaneous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epoetin alfa (SC) once per week (n = 20)
Trial: 7645538
Drug: Subcutaneous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epoetin alfa (SC) diluted 1:2 with bacteriostatic saline (n = 23)
Trial: 7645538
Drug: Subcutaneous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epoetin alfa (SC) three times per week (n = 24)
Trial: 2482270
Drug: Spray fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray fixation (Vale Smear Fix)
Trial: 688892
Drug: Atropine 0.5
RxNorm normalized name: homatropine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.5 mg, hyoscine-N-butylbromide 20 mg, and diazepam 5 mg (Group I)
Trial: 688892
Drug: Hyoscine-N-butylbromide 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine-N-butylbromide 20 mg and diazepam 5 mg (Group II)
Trial: 688892
Drug: Diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 5 mg and glucagon 0.2 mg (Group III)
Trial: 688892
Drug: Only diazepam
RxNorm normalized name: Product containing only diazepam (medicinal product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only diazepam 5 mg intravenously (Group IV)
Trial: 31017657
Drug: Adalimumab 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 0.8 mg/kg (40 mg maximum) every other week
Trial: 31017657
Drug: Adalimumab 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 0.4 mg/kg (20 mg maximum) every other week
Trial: 31017657
Drug: Methotrexate 0.1-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 0.1-0.4 mg/kg (25 mg maximum) weekly
Trial: 25769363
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (635 nm), treated twice a week for 3 weeks (total of 6 treatments)
Trial: 22194126
Drug: Botox (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox (current formulation)
Trial: 16938126
Drug: PZ levels
RxNorm normalized name: PZ-128
DrugBank: PZ-128 (DB11839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ levels below the 5.0 percentile (0.52 microg mL‐1)
Trial: 16938126
Drug: PZ levels
RxNorm normalized name: PZ-128
DrugBank: PZ-128 (DB11839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ levels below the 2.5 percentile (0.47 microg mL‐1)
Trial: 15491435
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (75 mg)
Trial: 11131270
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker treatment during the study
Trial: 8519378
Drug: Shortened time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened time interval between dose steps (3 min)
Trial: 30718539
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of rTMS and ABM training
Trial: 30718539
Drug: ABM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABM treatment
Trial: 17364399
Drug: HIV medication
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV medication adherence
Trial: 16289803
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for chronic pain
Trial: 12109952
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (5 mg bolus injections at 5 min intervals)
Trial: 10546840
Drug: Intramuscular artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular artemether (3.2‐mg/kg loading dose followed by 1.6 mg/kg daily)
Trial: 10546840
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (20‐mg/kg loading dose followed by 10 mg/kg every 8 h)
Trial: 8696533
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering treatment (group C, n = 22)
Trial: 8696533
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group A, n = 52)
Trial: 8696533
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering treatment (group C)
Trial: 1978497
Drug: Remoxipride 100-300
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 100-300 mg/day (n = 60)
Trial: 1978497
Drug: Remoxipride 200-600
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 200-600 mg/day (n = 61)
Trial: 1978497
Drug: Haloperidol 10-30
RxNorm normalized name: haloperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 10-30 mg/day (n = 64)
Trial: 351394
Drug: Aspirin (Men)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (Men)
Trial: 351394
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Aspirin and Sulfinpyrazone
Trial: 31694579
Drug: Colonoscopy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonoscopy without prophylactic antibiotics
Trial: 26267731
Drug: Methotrexate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (up to 25 mg/week orally)
Trial: 21331473
Drug: Fast-dissolving azithromycin
RxNorm normalized name: melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fast-dissolving azithromycin gelatin capsules
Trial: 21331473
Drug: Commercial azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercial azithromycin gelatin capsules
Trial: 16983108
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 every 3 weeks
Trial: 15090933
Drug: Riluzole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (50 mg bid)
Trial: 8148228
Drug: Yohimbine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (10 mg)
Trial: 8148228
Drug: Yohimbine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (4 mg)
Trial: 2844548
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) (all doses)
Trial: 21386999
Drug: Adenosine A(2A)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in dyskinetic PD patients
Trial: 21386999
Drug: Adenosine A(2A)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in drug-naïve PD patients
Trial: 21386999
Drug: Adenosine A(2A)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET after antiparkinsonian therapy in drug-naïve PD patients
Trial: 18200673
Drug: 100 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL/d of 20% alanyl-glutamine dipeptide (AGD) intravenously for 10 days (early treatment group)
Trial: 17186738
Drug: Medicated bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated bath plus acupoint massage (B-M treatment)
Trial: 1629993
Drug: Drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatments for PTSD
Trial: 6512252
Drug: Isopropyl alcohol
RxNorm normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropyl alcohol skin preparation
Trial: 6512252
Drug: 0.5% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% chlorhexidine in 70% spirit skin preparation
Trial: 23046499
Drug: Dietary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary and lifestyle advice, monitoring of blood glucose, and further medical treatment for hyperglycaemia as appropriate.
Trial: 20329570
Drug: Oxycodone controlled-release
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone controlled-release (CR) administered orally twice daily for at least 28 days, dosage individualized and up-titrated over the first week.
Trial: 20329570
Drug: Oxycodone controlled-release
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone controlled-release (CR)
Trial: 16845791
Drug: Diacerein (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein (100 mg/d)
Trial: 16845791
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (75 mg/d)
Trial: 1617932
Drug: roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150 mg twice daily
Trial: 1617925
Drug: erythromycin 1
RxNorm normalized name: erythromycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythromycin 1 g twice daily
Trial: 6150717
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine daily for 5 days
Trial: 6150717
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg cimetidine daily for 5 days
Trial: 25358916
Drug: Treatment initiation
RxNorm normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiation (pharmacotherapy and/or psychotherapy)
Trial: 25358916
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (pharmacotherapy and psychotherapy)
Trial: 23154888
Drug: Levothyroxine oral
RxNorm normalized name: levothyroxine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine oral solution (600 mcg)
Trial: 23154888
Drug: Levothyroxine tablets
RxNorm normalized name: levothyroxine Oral Tablet
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine tablets (600 mcg)
Trial: 23154888
Drug: Levothyroxine soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine soft gel capsules (600 mcg)
Trial: 20054522
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment group (CON)
Trial: 15814044
Drug: 2 days
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of oral ofloxacin (10 mg/kg/day)
Trial: 15814044
Drug: 3 days
RxNorm normalized name: Transderm Scop 1mg/3 days Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of oral ofloxacin (10 mg/kg/day)
Trial: 8606849
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol therapy
Trial: 8606849
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CF patients not receiving albuterol therapy)
Trial: 28862017
Drug: Adherence support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence support and nutritious food supplement
Trial: 27688102
Drug: Panitumumab +
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panitumumab + docetaxel/cisplatin chemotherapy
Trial: 27688102
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (docetaxel/cisplatin)
Trial: 15678730
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine with fentanyl 2 microg mL(-1) at 10 mL h(-1) (Group R1, n = 38)
Trial: 15678730
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine with fentanyl 2 microg mL(-1) at 8 mL h(-1) (Group R2, n = 39)
Trial: 11770217
Drug: Economic assessment
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Economic assessment of treatments for lung cancer
Trial: 9640992
Drug: High-dose alprazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alprazolam
Trial: 9640992
Drug: Low-dose alprazolam
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alprazolam
Trial: 9640992
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with high-dose alprazolam
Trial: 9640992
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with lorazepam
Trial: 9640992
Drug: Single high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single high and low doses of alprazolam and lorazepam
Trial: 8136599
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine plus normal saline solution
Trial: 8136599
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine plus sodium bicarbonate solution